New Japanese Study Suggests mRNA Vaccines Caused Huge Spike in Cancer Cases
The new study shows increased age-adjusted cancer mortality after the third mRNA-lipid nanoparticle vaccine dose in Japan.
A brand new study by Cureus, the Journal of Medical Science which publishes credible medical science. — Has released a huge study which suggests the spike in Cancer cases in Japan could’ve been caused by the mRNA vaccine.
The study utilised official statistics from Japan, comparing observed annual and monthly Antimicrobial Resistance (AMRs) with predicted rates based on pre-pandemic data from 2010 to 2019. The findings, obtained through logistic regression analysis, revealed notable patterns in cancer mortality rates during the “pandemic period.”
The first year of the so-called pandemic, 2020, showed no significant excess mortality related to cancer. However, in 2021, after the mass vaccination campaign with the first and second vaccine doses, some excess cancer mortalities were observed.
The trend intensified in 2022.
In particular, following the administration of the third vaccine dose, significant excess mortalities were noted across all cancers and specific types, including ovarian, leukaemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers.
AMRs for the four cancers with the highest mortality rates—lung, colorectal, stomach, and liver—exhibited a decreasing trend until 2020. However, this decline slowed in subsequent years, indicating a potential impact of the pandemic on cancer mortality rates.
The COVID-19 pandemic, which began in Wuhan, China, in December 2019, reached Japan in January 2020. In response, the Japanese government implemented various healthcare and socio-economic restrictions in an attempt to mitigate the spread of the virus. Since February 2021, the mRNA-lipid nanoparticle (mRNA-LNP) vaccine has been available for emergency use, with a significant portion of the population receiving multiple doses by March 2023.
Despite these efforts, Japan reported 33.8 million COVID-19 infections and according to their data, 74,500 deaths were attributed to the virus by April 2023. Additionally, excess deaths from causes other than COVID-19, including cancer, have been documented globally.
Cancer is the leading cause of death in Japan.
This leading cause warrants particular attention, given its prevalence and impact on public health. Understanding the effects of the “pandemic” on cancer mortality rates is crucial, especially considering Japan's large population, availability of official statistics, and high accuracy rate of death certificates.
![](https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4d271c92-0a99-4932-94c2-e08669f5c438_1490x1404.png)
The statistical findings on cancer deaths in 2021-2022 can be summarised as follows:
According to the study, “All cancer deaths: A statistically significant excess emerged in 2021 and increased further in 2022. In addition, significant excess monthly mortality was observed after August 2021, whereas mass vaccination of the general population began around April 2021. There were excess trends in cancer deaths across most age groups. However, these trends were only statistically significant for age groups with the highest cancer mortality: the 75-79 age group in 2021 and the 75-84 age group in 2022. More than 90% of people over 70 years of age have received the third vaccine dose.”
They observed a significant increase in age-adjusted mortality rates (AMRs) for ovarian cancer, leukaemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers, particularly in 2022. These cancers are known as oestrogen and oestrogen receptor alpha (ERα)-sensitive cancers. Recent research indicates that the SARS-CoV-2 spike protein (S-protein) binds specifically to ERα. This interaction may induce endogenous DNA double-strand breaks (DSBs) in ER-sensitive cancers, potentially increasing cancer risk.
Furthermore, concerns arise regarding dysfunction in crucial cancer suppressor genes, such as BRCA1, BRCA2, and P53, possibly due to interactions with the S-protein. Dysfunction in these genes is associated with a higher risk of various cancers, including breast, ovarian, prostate, and pancreatic cancers.
The U.S. Food and Drug Administration (FDA) has highlighted potential oncogenic risks associated with residual DNA in viral vaccines. Recent reports indicate the presence of double-stranded DNA fragments from residual plasmid vectors in certain lots of Pfizer-BioNTech and Moderna vaccines, exceeding regulatory limits set by the FDA.
Further investigation is needed to determine the potential link between observed excess cancer deaths following mass vaccination and reported residual DNA in the vaccine.
The findings underscore the importance of understanding the potential oncogenic effects of mRNA COVID-19 vaccines and the need for continued research to ensure vaccine safety and efficacy.
Subscribe to this Substack to receive weekly content on Politics, culture and agendas. — You will be supporting independent, contrarian journalism attempting to make a difference. Paid subscribers will be able to comment and have access to exclusive content in the future.